Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2015

View Archived Issues

NO-donating bimatoprost shows preclinical efficacy reducing IOP

FDA designates Cidara's CD-101 IV as QIDP

Lilly and BioNTech form cancer immunotherapy collaboration

NAPs show promising sequence-independent antiviral activity

Retrophin introduces compounds for the treatment of neurodegeneration

Roche patents CYP11B2 inhibitors

Astellas to access Cyclenium's macrocycle drug discovery technologies

Roivant Sciences licenses nelotanserin from Arena Pharmaceuticals

Sumitomo Dainippon Pharma profiles progress of fourth quarter of fiscal 2014

Celprogen reveals pancreatic stem cell stimulator STEMC-7007

Data on REGN-844 for dry eye disease reported

PIM-447 shows potential for the treatment of MM

Merck & Co. discloses ROM-K channel blockers

Michael J. Fox Foundation acquires research tools from Imago

Dana-Farber, Syros Pharmaceuticals and Paraza Pharma jointly patent CDK7 inhibitors

Evofosfamide receives FDA fast track designation for pancreatic cancer

Shionogi prepares and tests ACC2 inhibitors

Astellas Pharma discloses GABA(B) positive allosteric modulators

Intravitreal CD34+ autologous bone marrow-derived cells safe in dry AMD patients

MorphoSys completes acquisition of Lanthio Pharma

FDA advisory committee recommends approval of Orkambi for cystic fibrosis

Preliminary phase I results of Ebola prime-boost vaccine regimen of MVA-BN Filo and AdVac

Takeda terminates phase III trial of alisertib in peripheral T-cell lymphoma

Fibrocell's FCX-007 receives rare pediatric disease designation from the FDA

FDA awards orphan drug designation to SemiAlloGen's approach to targeting glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...